Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:COSCVE:PASNYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/APASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePASPascal Biosciences0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOSCanadian Oil Sands 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOSCanadian Oil SandsN/AN/A0.00N/AN/AN/AN/AN/AN/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOSCanadian Oil SandsN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOSCanadian Oil SandsN/AN/AN/APASPascal Biosciences882.790.030.17SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOSCanadian Oil SandsN/APASPascal BiosciencesN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipCOSCanadian Oil SandsN/APASPascal Biosciences15.43%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOSCanadian Oil Sands147,000N/AN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableCOS, HEMO, PAS, SYN, and LCT HeadlinesRecent News About These CompaniesControversial ‘Synthetic Human Genome Project’ Spurs Debate Over Ethics of Building Human DNA from ScratchJuly 2 at 9:04 AM | thedebrief.orgTOn The Punt: Gilbert Gardiner's tips for Ballarat Synthetic on TuesdayJuly 2 at 9:04 AM | punters.com.auPSynthetic data, real results: Rewiring industrial inspection to work with AIJuly 1 at 2:40 PM | imveurope.comIUK launches bold Synthetic Human Genome Project: Can human DNA be built from scratch?June 27, 2025 | indiatvnews.comIAstroTurf Secures Historic Partnership as Official Synthetic Turf of Major League BaseballJune 27, 2025 | sfexaminer.comSSynthetic DNA research could lead to the creation of artificial life, Irish professor saysJune 27, 2025 | independent.ieIWhich mesh is best? Outcomes for abdominal ventral hernia repair patients projected by new research modelJune 25, 2025 | medicaldialogues.inMEULAR Updates Recommendations for Managing Rheumatoid ArthritisJune 20, 2025 | medscape.comMBenefits of early biologic treatment in psoriatic arthritis examined in studiesJune 12, 2025 | medicalxpress.comMWhich mesh is best? New research model projects outcomes for abdominal ventral hernia repair patientsJune 4, 2025 | msn.comBioNext: Generics to biologics, India’s moment to leadMay 26, 2025 | msn.comBiologics, Targeted Therapies Best for Acute PsA DactylitisMay 21, 2025 | medscape.comMInfection Patterns Matter in Selection of Advanced Therapies for Inflammatory ArthritisMay 16, 2025 | medscape.comMAnsa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA OrdersMay 11, 2025 | genengnews.comGMaxim Group Downgrades Theriva Biologics (TOVX)May 9, 2025 | msn.comAI and Machine Learning as Transformative BioToolsMay 7, 2025 | genengnews.comGCytiva and Asimov collaborate on next generation cell line design and process developmentApril 30, 2025 | pharmiweb.comPCytiva and Asimov Collaborate on NextGen Cell Line Design and Process DevelopmentApril 29, 2025 | genengnews.comGSynthetic Design emerges with $20M and next-gen ADC platformApril 26, 2025 | bioworld.comBSeries A financing at Grove BiopharmaApril 25, 2025 | bioworld.comBMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeNew All-Time Highs Coming for Broadcom? Wall Street Says YesBy Leo Miller | June 20, 2025View New All-Time Highs Coming for Broadcom? Wall Street Says YesCostco at a Crossroads: Is the Next Move Higher or Lower?By Dan Schmidt | June 25, 2025View Costco at a Crossroads: Is the Next Move Higher or Lower?Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs3 Utilities Stocks With Big Earnings, Balanced RiskBy Nathan Reiff | June 5, 2025View 3 Utilities Stocks With Big Earnings, Balanced RiskCOS, HEMO, PAS, SYN, and LCT Company DescriptionsCanadian Oil Sands TSE:COSConiagas Battery Metals Inc. recently discovered a major high-grade nickel-copper deposit with cobalt, platinum and palladium byproduct near Saguenay in Northern Quebec. The deposit stretches along a 6 km strike length of shallow mineralization suitable for an open-pit mine. It also sits on top of a very large and deep gravity anomaly with the potential for much more and higher-grade mineralization deeper. Geologists believe the deposit has the potential to be a major mine supplying critical metals for the energy transition.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
